Semaglutide, a prescription drug currently used as part of a type 2 diabetes treatment, spent some time in the spotlight at this year’s virtual European Congress on Obesity (held May 10-13, 2021). The reason was that this medication has been undergoing study as an obesity treatment as well, and the results have been promising so far.
(more…)